HY-R01337-5nmol
|
MedChemexpress LLC
|
hsa-miR-4734 mimic
|
|
Cancer-programmed cell death
|
|
HY-R01338A-20nmol
|
MedChemexpress LLC
|
hsa-miR-4735-3p agomir
|
|
|
|
HY-R01338A-5nmol
|
MedChemexpress LLC
|
hsa-miR-4735-3p agomir
|
|
|
|
HY-RI01338A-20nmol
|
MedChemexpress LLC
|
hsa-miR-4735-3p antagomir
|
|
|
|
HY-RI01338A-5nmol
|
MedChemexpress LLC
|
hsa-miR-4735-3p antagomir
|
|
|
|
HY-RI01338-20nmol
|
MedChemexpress LLC
|
hsa-miR-4735-3p inhibitor
|
|
|
|
HY-RI01338-5nmol
|
MedChemexpress LLC
|
hsa-miR-4735-3p inhibitor
|
|
|
|
HY-R01338-20nmol
|
MedChemexpress LLC
|
hsa-miR-4735-3p mimic
|
|
Cancer-programmed cell death
|
|
HY-R01338-5nmol
|
MedChemexpress LLC
|
hsa-miR-4735-3p mimic
|
|
Cancer-programmed cell death
|
|
HY-R01339A-20nmol
|
MedChemexpress LLC
|
hsa-miR-4735-5p agomir
|
|
|
|
HY-R01339A-5nmol
|
MedChemexpress LLC
|
hsa-miR-4735-5p agomir
|
|
|
|
HY-RI01339A-20nmol
|
MedChemexpress LLC
|
hsa-miR-4735-5p antagomir
|
|
|
|
HY-RI01339A-5nmol
|
MedChemexpress LLC
|
hsa-miR-4735-5p antagomir
|
|
|
|
HY-RI01339-20nmol
|
MedChemexpress LLC
|
hsa-miR-4735-5p inhibitor
|
|
|
|
HY-RI01339-5nmol
|
MedChemexpress LLC
|
hsa-miR-4735-5p inhibitor
|
|
|
|
HY-R01339-20nmol
|
MedChemexpress LLC
|
hsa-miR-4735-5p mimic
|
|
Cancer-programmed cell death
|
|
HY-R01339-5nmol
|
MedChemexpress LLC
|
hsa-miR-4735-5p mimic
|
|
Cancer-programmed cell death
|
|
HY-R01340A-20nmol
|
MedChemexpress LLC
|
hsa-miR-4736 agomir
|
|
|
|
HY-R01340A-5nmol
|
MedChemexpress LLC
|
hsa-miR-4736 agomir
|
|
|
|
HY-RI01340A-20nmol
|
MedChemexpress LLC
|
hsa-miR-4736 antagomir
|
|
|
|
HY-RI01340A-5nmol
|
MedChemexpress LLC
|
hsa-miR-4736 antagomir
|
|
|
|
HY-RI01340-20nmol
|
MedChemexpress LLC
|
hsa-miR-4736 inhibitor
|
|
|
|
HY-RI01340-5nmol
|
MedChemexpress LLC
|
hsa-miR-4736 inhibitor
|
|
|
|
HY-R01340-20nmol
|
MedChemexpress LLC
|
hsa-miR-4736 mimic
|
|
Cancer-programmed cell death
|
|
HY-R01340-5nmol
|
MedChemexpress LLC
|
hsa-miR-4736 mimic
|
|
Cancer-programmed cell death
|
|